Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

IGM Biosciences Q2 EPS $(1.16) Down From $(0.62) YoY

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.16) per share. This is a 87.1 percent decrease over losses of $(0.62) per share from the same period last year.
byBenzinga Newsdesk
August 9, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.16) per share. This is a 87.1 percent decrease over losses of $(0.62) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Preview: Novagold Resources’s Earnings

By Benzinga Insights
Today, 10:41 PM
Novagold Resources (AMEX:NG) is set to give its latest quarterly earnings report on Wednesday, 2022-06-29. Here's what investors need to know before the announcement. Analysts estimate that Novagold Resources will report an earnings per share (EPS) of $-0.03.

NG

Read More

NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer; Primary Endpoint Met

By Charles Gross
Today, 10:41 PM
NEJM Evidence has published results from the QUILT 3.032 trial studying N-803 plus BCG in adults with NMIBC CIS with or without Ta/T1 papillary disease. These positive data form the basis of ImmunityBio's BLA for BCG-unresponsive NMIBC CIS, which the FDA accepted for review in July 2022.

IBRX